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Editorial
Delivery of Nucleic Acids
Nucleic acids have revolutionized biomedical research
and have become indispensable research tools. In
pharmaceutical development, nucleic acids are at present
mostly used as diagnostic tools and for target validation (1–
3). Applications of microarrays and PCR, treatment with
antisense oligonucleotides or small interfering RNA and
breeding of knock-in/knock-out-models can be used for
accurate diagnosis and biomarker detection, can improve
insight into disease processes and can pinpoint pathways
where treatments may interfere. Although the application of
nucleic acids as therapeutics promises to be even more
exciting, their role as clinically applied drugs is still modest.
At present, two nucleic acid-based drugs (Vitravenei
and Macugeni) are on the market (4). Both drugs are
oligonucleotides. Macugeni is an extracellularly acting
aptamer that functions as a growth factor decoy and
Vitravenei is an intracellularly acting antisense molecule
that inhibits a viral gene. Both oligonucleotides contain
chemically modiﬁed backbones and are injected at the site
of the pathology in the vitreous of the eye. This exempliﬁes
the difﬁculties associated with the use of nucleic acids for
therapeutic intervention, both regarding their physicochem-
ical as well as their biological properties.
The physicochemical properties of nucleic acids, with
molecular weights ranging from 7 kDa for antisense oligo-
nucleotides to over 1 MDa for plasmid DNA, and strong
negative charge do not favor membrane passage. Only one
class of nucleic acids, aptamers, can act extracellularly, which
circumvents the need for cell membrane translocation.
Conversely, all other classes need to interact with intracellu-
lar targets to be active. The problem is most prominent for
plasmid DNA, which has the largest size of all proposed
nucleic acid therapeutics and also needs to arrive inside the
cell nucleus to be effective. Nuclear localization would in
principle require passage through the nuclear pore for which
the DNA-molecule is too large (5). These qualities at least
partly explain why the marketed drugs are an aptamer and an
antisense oligonucleotide.
The biological properties also do not support their
application as therapeutics. Nucleic acids are susceptible to
the action of nucleases. Therefore the two marked oligonu-
cleotides bear chemically modiﬁed backbones. In addition,
nucleic acids are rapidly cleared from the body, either via
glomerular ﬁltration by the kidneys and excretion into the
urine or by (scavenger) receptor uptake and intracellular
degradation. Therefore, local injection at the site of the
pathology is the preferred administration route for the
clinically applied oligonucleotides.
Despite these difﬁculties, nucleic acids still capture the
mind of many pharmaceutical scientists as possible therapeu-
tics. One of the most appealing properties is that a change in a
disease target would in principle only require a change in the
nucleic acid sequence to obtain a new drug. As the physico-
chemical properties like size and charge of the molecules
remainthesame,thesameprinciplescan beappliedduring the
drug formulation steps for this new sequence. After successful
formulation of the ﬁrst nucleic acid drug it can be expected
that subsequent formulations will follow more easily. In
contrast, for small molecular weight drugs, lead compound
identiﬁcation requires high throughput screening, and drug
formulation is dependent on the physicochemical and biolog-
ical characteristics of the compound.
Nevertheless, the difﬁcult biopharmaceutical character-
istics of nucleic acids put a lot of demands on the delivery
systems that should compensate for these qualities by
increasing stability against the action of nucleases, reducing
excretion and uptake by non-target tissues and promoting
target tissue interaction, target cell association, membrane
translocation, and correct intracellular trafﬁcking (6). The
articles in this theme issue address this difﬁcult drug
formulation process.
The group of Klibanov approached the problem of
identifying suitable vectors for plasmid DNA delivery using
a high-throughput-synthesis coupled to combinatorial chem-
istry approach. Their study is based on the cationic polymer
poly(ethylene imine) (PEI). Experimental observations of
their group and others indicate that PEI molecular weight is
positively correlated with degree of transfection but also with
severity of toxicity (7, 8). These observations provided the
input for synthesizing small molecular weight PEI-derivatives
that were cross-linked with oligo-acrylate esters. As many of
the factors that contribute to degree of transfection and
toxicity as well as the relative contribution of each factor to
the overall transfection efﬁciency are unknown, the high-
throughput synthesis approach likely provides a higher
chance of ﬁnding successful polymers. Indeed, their results
show that superior PEI-derivatives could be identiﬁed as
compared to the presently used Fgolden standard_ 22 kD PEI
both with respect to degree of transfection as well as toxicity
both in vitro and in vivo.
Most cationic polymers exhibit a molecular weight
distribution. De Wolf et al. investigated the effects of
fractionation of the biodegradable polymer poly(2-dimethyl-
amino ethylamino)phosphazene (p(DMAEA)-ppz) into four
different molecular weight fractions on in vitro/in vivo
transfection of plasmid DNA and polymer-DNA-complex-
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toxicity proﬁle were observed for the various molecular
weights. Clear correlation between molecular weight and
toxicity was seen, whereas degree of transfection was
dependent on toxicity and colloidal stability of the com-
plexes. These results underline that there is a strong need to
use polymers with deﬁned molecular weights and narrow
distributions to be able to accurately determine the value of a
speciﬁc polymer as nucleic acid carrier.
Dendritic a,(-poly(L-lysine)s were the subject of investi-
gation as possible oligonucleotide vectors in the study of
Eom et al. In this study they compared a panel of dendrimers
varying in generation and number of poly-L-lysine units in
the core with respect to their effectiveness regarding delivery
of an antisense oligonucleotide that modiﬁes splicing in the
nucleus. The advantage of studying this with dendrimers is
the monodisperse character and speciﬁed architecture of the
polymer, circumventing the difﬁculties in interpreting results
identiﬁed by de Wolf et al. In addition, amino-acid deriva-
tives can be easily prepared which allows gaining insight on
the rate-limiting steps of the transfection process in relation
to polymer character. It appeared that both charge-density of
dendrimers and molecular weight are positively correlated to
antisense activity. The most successful hyperbranched, high
generation dendrimers were shown to form compact particles
of approximately 70 nm with the antisense oligonucleotide,
which showed colloidal stability in the presence of serum
which is an important quality for in vivo application. In
addition, the particles enhanced antisense accumulation in
the nucleus. Importantly, the optimal dendrimer did not show
toxicity when complexed to the antisense oligonucleotide in
vitro. Similar dendrimeric structures have also been com-
plexed to plasmid DNA which yielded much larger struc-
tures, that still effectuated efﬁcient gene transfection and
limited toxicity (9).
The various strategies described above to identify and
characterize efﬁcient vectors for oligonucleotides or plasmid
DNA largely treat transfection and toxicity as a black box,
where the net transfection efﬁciency is the overall result of
different processes inside the cell. The ﬁrst step towards gene
transfection is cell association and uptake of the gene carriers.
Depending on their surface characteristics and size, gene
carriers can be taken up via different endocytic routes,
including clathrin-or caveolae-dependent endocytosis, macro-
pinocytosis and phagocytosis. However, not all routes of
uptake may lead to effective release of nonviral carriers and
its associated DNA required for transgene expression. Van
derAa et al. have looked into the cellular uptake mechanisms
of two well established cationic polymers used for DNA
transfection, namely polyethyleneimine (PEI) and poly(2-
(dimethylamino)ethyl methacrylate) (pDMAEMA). They
showed by spectral bio-imaging that both DNA carriers were
internalized in COS-7 cells via clathin- and caveolae-depen-
dent pathways. Blocking either routes of uptake with speciﬁc
uptake inhibitors resulted in only marginal decrease in the
total amount of polyplexes that were internalized, suggesting
that uptake routes may be interchangeable. However, block-
ing the caveolae-dependent uptake route resulted in complete
loss of gene transfection, whereas blocking the clathrin-
dependent uptake route did not show a signiﬁcant reduction
in gene expression. This shows that the caveolae-dependent
uptake pathway is the preferred route for obtaining gene
transfection in COS-7 cells. These ﬁndings have implications
for the development of new or improvement of existing gene
carriers. Increased gene transfection efﬁciencies may be
obtained by speciﬁcally steering gene carriers towards pre-
ferred uptake routes. Although it is at present still unclear
which factors determine the uptake pathway that is being
followed, the size of the gene carriers seems to play an
important role (10). However, cellular factors and surface
characteristics of the gene carriers also have an effect on the
way these carriers are being internalized. Nevertheless, the
study by van der Aa et al. shows that by focusing in on single
steps of the multistep process leading to gene transfection,
valuable information can be obtained that can be used to
further optimize nucleic acid delivery vectors.
The majority of nucleic acid therapeutics are to a higher
degree dependent on delivery systems for successful thera-
peutic intervention than conventional drugs. The transfection
efﬁciency of currently used delivery systems is still too low
for many clinical applications. Therefore, new delivery agents
are needed that combine a high degree of transfection with
acceptable toxicity proﬁles. Combinatorial chemistry could
provide important input to identify such compounds. These
new delivery agents should be well characterized regarding
their physicochemical and structural characteristics and
should ideally be adapted to the nucleic acid payload (e.g.
plasmid or oligonucleotide) to optimally tailor delivery
needs. Important information on the delivery needs and rate
limiting steps of the transfection process can be obtained by
in depth analysis of the intracellular trafﬁcking of nucleic
acids. Ultimately all these aspects of nucleic acid carrier
design should come together to develop safe and clinically
effective nucleic acid therapeutics.
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